ResearchTechCrunch

“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

#ai#biotech#investment#personalized medicine#drug development

English

Vijay Pande, previously managing $4 billion at a16z, has shifted to a smaller investment strategy with his new firm VZVC, focusing on concentrated bets rather than numerous investments. He emphasizes the role of AI in advancing personalized medicine and the challenges of drug development, particularly the limitations of animal models in predicting human responses.

中文

维贾伊·潘德曾在a16z管理40亿美元，现在转向了他的新公司VZVC，采用集中投资而非大量投资的策略。他强调了人工智能在推进个性化医学中的作用，以及药物开发面临的挑战，特别是动物模型在预测人类反应方面的局限性。